Treatment of irritable bowel syndrome: a review of randomised controlled trials (Q34130605)

31 July 2017

1 reference

title

Treatment of irritable bowel syndrome: a review of randomised controlled trials (English)

1 reference

randomized controlled trial

31 July 2017

1 reference

inferred from title

irritable bowel syndrome

1 reference

Akehurst R

1

1 reference

PubMed ID

11156653

31 July 2017

Kaltenthaler E

series ordinal

2

1 reference

PubMed ID

11156653

31 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

31 July 2017

1 reference

31 July 2017

48

1 reference

31 July 2017

2

1 reference

31 July 2017

272-282

1 reference

Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis

31 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Metronidazole relieves symptoms in irritable bowel syndrome: the confusion with so-called 'chronic amebiasis'.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Review article: irritable bowel syndrome

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Calcium polycarbophil compared with placebo in irritable bowel syndrome.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Irritable bowel, irritable body, or irritable brain?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Double blind study of ispaghula in irritable bowel syndrome

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled crossover study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Double-blind study of an alpha 2 agonist in the treatment of irritable bowel syndrome

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Ranking of symptoms by patients with the irritable bowel syndrome

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

The treatment of irritable colon. Efficacy and tolerance of buscopan plus, buscopan, paracetamol and placebo in ambulatory patients with irritable colon

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. A controlled, crossover study.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

"Prokinetic" treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

The efficacy of Plantago ovata as a regulator of intestinal transit. A double-blind study compared to placebo

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Otilonium bromide-diazepam in the treatment of the irritable colon. A controlled study versus otilonium bromide

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Towards positive diagnosis of the irritable bowel

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Antidepressants for functional gastrointestinal syndromes.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728206

Therapy of irritable bowel syndrome--an overview

28 October 2018

1 reference

12 December 2020

Irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker. A randomized double-blind placebo-controlled trial

1 reference

12 December 2020

A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin

1 reference

12 December 2020

Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron)

1 reference

12 December 2020

Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome

1 reference

12 December 2020

[Treatment of irritable colon with lidamidine and support psychotherapy]

1 reference

12 December 2020

The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation

1 reference

12 December 2020

Effects of desipramine on irritable bowel syndrome compared with atropine and placebo

1 reference

12 December 2020

Loperamide treatment of the irritable bowel syndrome

1 reference

12 December 2020

Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome

1 reference

12 December 2020

[Treatment of irritable bowel syndrome with peppermint oil. A double-blind study with a placebo]

1 reference

12 December 2020

Paraghurt for patients with irritable bowel syndrome. A controlled clinical investigation from general practice

1 reference

12 December 2020

[Effect of a buzepide metiodide-haloperidol combination in treating functional intestinal disorders. Randomized double-blind controlled versus placebo study]

1 reference

12 December 2020

Long-term treatment of irritable bowel syndrome: results of a randomized controlled trial

1 reference

12 December 2020

The efficacy of amineptine in the treatment of depressive patients with irritable bowel syndrome

1 reference

12 December 2020

A comparison of mebeverine with high-fibre dietary advice and mebeverine plus ispaghula in the treatment of irritable bowel syndrome: an open, prospectively randomised, parallel group study

1 reference

12 December 2020

Double-blind cross-over trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance

1 reference

12 December 2020

Aleatory clinical study comparing otilonium bromide with a fiber-rich diet in the treatment of irritable bowel syndrome

1 reference

12 December 2020

Stress Management for Irritable Bowel Syndrome: A Controlled Trial

1 reference

12 December 2020

Effects of cimetropium bromide on gastrointestinal transit time in patients with irritable bowel syndrome

1 reference

12 December 2020

Octylonium bromide in the treatment of the irritable bowel syndrome: a clinical-functional study

1 reference

12 December 2020

Loxiglumide, a CCK-A Antagonist, in Irritable Bowel Syndrome

1 reference

12 December 2020

Effect of leuprolide acetate in patients with moderate to severe functional bowel disease. Double-blind, placebo-controlled study

1 reference

12 December 2020

Effect of leuprolide acetate in patients with functional bowel disease. Long-term follow-up after double-blind, placebo-controlled study

1 reference

12 December 2020

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

1 reference

12 December 2020

Bran supplementation in the treatment of irritable bowel syndrome

1 reference

12 December 2020

A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome

1 reference

12 December 2020

Identifiers

DOI

10.1136/GUT.48.2.272

1 reference

31 July 2017

1 reference

31 July 2017

1 reference

PubMed ID

11156653